drugset / Trial / NCT05030246
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Surufatinib combined with Toripalimab in patients with peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.
Timeline
- Start
- 2021-07-14
- Primary completion
- 2023-04-30
- Completion
- 2023-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |